Influence of mirtazapine on salivary cortisol in depressed patients

Neuropsychobiology

Volumn 47, Issue 1, 2003, Pages 31-36

  Laakmann, G ^a   Hennig, J ^b   Baghai, T ^a   Schüle, Cornelius ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cortisol; Depressive disorder; Mirtazapine; Saliva; Treatment response

Indexed keywords

CLOMIPRAMINE; DESIPRAMINE; HYDROCORTISONE; INDALPINE; MIRTAZAPINE; NOMIFENSINE; OXAPROTILINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; HYDROCORTISONE RELEASE; HYDROCORTISONE SALIVA LEVEL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR DEPRESSION; MALE; MONOTHERAPY; PRIORITY JOURNAL; RATING SCALE; SALIVA ANALYSIS; SALIVA LEVEL; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; HYDROCORTISONE; MALE; MIANSERIN; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SALIVA; TREATMENT OUTCOME;

EID: 0344080439     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068873     Document Type: Article

References (52)

1. Tuomisto J, Mannisto P: Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985;37:249-332.
2. Hyttel J: Citalopram - Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-295.
3. Laakmann G, Schon HW, Wittmann M: Desipramine and growth hormone secretion. Lancet 1981;2:996.
4. Laakmann G: Psychopharmacoendocrinology and depression research. Monogr Gesamtgeb Psychiatr Psychiatry Ser 1988;46:1-220. In German.
5. De Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995;10(suppl 4):19-23.
6. De Boer T, Ruigt GSF, Berendsen HHG: The α-2 selective adrenoceptor antagonist Org 3770 (mirtazapine Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995;10(suppl 2):107-119.
7. De Boer TH, Nefkens F, Van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the α-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996;277:852-860.
8. Haddjeri N, Blier P, de Montigny C: Effect of the α-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 1996;277:861-871.
9. Haddjeri N, Blier P, de Montigny C: Effects of long-term treatment with the α-2 adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 1997;355:20-29.
10. De Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988;27:399-408.
11. Timmer CJ, Paanakker JE, Vrijmoed-de Vries M: Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. Pharm Res 1997;14:98-102.
12. Laakmann G, Schule C, Baghai T, Waldvogel E: Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999;24:769-784.
13. Schüle C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G: The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 2002;163:95-101.
14. Laakmann G, Wittmann M, Schoen HW, Zygan K, Weiss A, Meissner R, Mueller OA, Stalla GK: Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humans. 3. Hypothalamo-pituitary-adrenocortical axis. Psychoneuroendocrinology 1986;11:475-489.
15. Hennig J, Lange N, Haag A, Rohrmann S, Netter P: Reboxetine in a neuroendocrine challenge paradigm: Evidence for high cortisol responses in healthy subjects scoring high on subclinical depression. Int J Neuropsychopharmacol 2000;3:193-201.
16. Hennig J, Netter P: Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. Int J Neuropsychopharmacol 2002;5:67-71.
17. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501.
18. Gibbons JL, McHugh PR: Plasma cortisol in depressive illness. J Psychiat Res 1962;1:162-171.
19. Doig RJ, Mummery RV, Willis MR, Elkes A: Plasma cortisol levels in depression. Br J Psychiatry 1966;112:1263-1267.
20. Butler PW, Besser GM: Pituitary-adrenal function in severe depressive illness. Lancet 1968;i:1234-1236.
21. Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukushima DK, Gallagher TF: Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 1973;28:19-24.
22. Carroll BJ, Curtis GC, Mendels J: Cerebrospinal fluid and plasma free cortisol concentrations in depression. Psychol Med 1976;6:235-244.
23. Stokes PE, Stoll PM, Koslow SH, Maas JW, Davis JM, Swann AC, Robins E: Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A multicenter study. Arch Gen Psychiatry 1984;41:257-267.
24. Carroll BJ, Mendels J: Neuroendocrine regulation in affective disorder; in Sachar EJ (ed): Hormones, behavior and psychopathology. New York, Raven Press, 1976.
25. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, Steiner M, de Vigne JP, Young E: A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38:15-22.
26. Brown WA, Shuey I: Response to dexamethasone and subtype of depression. Arch Gen Psychiatry 1980;37:747-751.
27. Holsboer F, Bender W, Benkert O, Klein HE, Schmauss M: Diagnostic value of dexamethasone suppression test in depression. Lancet 1980;ii:706.
28. Heuser I, Yassouridis A, Holsboer F: The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341-356.
29. World Medical Association: World Medical Association Declaration of Helsinki, ethical principles for medical research involving human subjects. Ferney-Voltaire, WMA, 2000. http://www.wma.net/e/policy/17-c_e.html.
30. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4 (revised). Washington, American Psychiatric Press, 1994.
31. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
32. Kirschbaum C, Strasburger CJ, Jammers W, Hellhammer DH: Cortisol and behavior: 1. Adaptation of a radioimmunoassay kit for reliable and inexpensive salivary cortisol determination. Pharmacol Biochem Behav 1989;34:747-751.
33. Asnis GM, Sachar EJ, Halbreich U, Nathan RS, Novacenko H, Ostrow LC: Cortisol secretion in relation to age in major depression. Psychosom Med 1981;43:235-242.
34. Halbreich U, Asnis GM, Zumoff B, Nathan RS, Shindledecker R: Effect of age and sex on cortisol secretion in depressives and normals. Psychiatry Res 1984;13:221-229.
35. Akil H, Haskett RF, Young EA, Grunhaus L, Kotun J, Weinberg V, Greden J, Watson SJ: Multiple HPA profiles in endogenous depression: Effect of age and sex on cortisol and β-endorphin. Biol Psychiatry 1993;33:73-85.
36. Jacobs S, Mason J, Kosten T, Brown S, Ostfeld A: Urinary free cortisol excretion in relation to age in acutely stressed persons with depressive symptoms. Psychosom Med 1984;46:213-221.
37. Laakmann G, Dieterle D, Weiss L, Schmauss M: Therapeutic and neuroendocrine studies using yohimbine and antidepressants in depressed patients and healthy subjects; in Langer SZ (ed): Advances in the Biosciences. Oxford, Pergamon Press, 1982, vol 40, pp 295-301.
38. Buckingham JC, Hodges JR: Hypothalamic receptors influencing the secretion of corticotrophin-releasing hormone in the rat. J Physiol 1979;290:421-431.
39. Jones MT, Birmingham M, Gillham B, Holmes M, Smith T: The effect of cyproheptadine on the release of corticotrophin releasing factor. Clin Endocrinol (Oxf) 1979;10:203-205.
40. Imura H, Nakai Y, Yoshimi T: Effect of 5-hydroxytryptophan (5-HTP) on growth hormone and ACTH release in man. J Clin Endocrinol Metab 1973;36:204-206.
41. Lewis DA, Sherman BM: Serotonergic stimulation of adrenocorticotropin secretion in man. J Clin Endocrinol Metab 1984;58:458-462.
42. Nakanishi S, Inoue A, Kita T, Nakamura M, Chang AC, Cohen SN, Numa S: Nucleotide sequence of cloned cDNA for bovine corticotropin-β-lipotropin precursor. Nature 1979; 278:423-427.
43. Cavagnini F, Raggi U, Micossi P, Di Landro A, Invitti C: Effect of an antiserotoninergic drug, metergoline, on the ACTH and cortisol response to insulin hypoglycemia and lysine-vasopressin in man. J Clin Endocrinol Metab 1976;43:306-312.
44. Krieger DT, Amorosa L, Linick F: Cyproheptadine-induced remission of Cushing's disease. N Engl J Med 1975;293:893-896.
45. Krieger DT, Luria M: Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson's syndrome. J Clin Endocrinol Metab 1976;43:1179-1182.
46. Berendsen HH, Kester RC, Peeters BW, Broekkamp CL: Modulation of 5-HT receptor subtype-mediated behaviours by corticosterone. Eur J Pharmacol 1996;308:103-111.
47. Kjaer A, Knigge U, Plotsky PM, Bach FW, Warberg J: Histamine H1 and H2 receptor activation stimulates ACTH and β-endorphin secretion by increasing corticotropin-releasing hormone in the hypophyseal portal blood. Neuroendocrinology 1992;56:851-855.
48. Allolio B, Deuss U, Kaulen D, Winkelmann W: Effect of meclastine, a selective H1 receptor antagonist, upon ACTH release. Clin Endocrinol (Oxf) 1983;19:239-245.
49. Reilly MA, Sigg EB: Suppression of histamine-induced adrenocorticotropic hormone release by antihistamines and antidepressants. J Pharmacol Exp Ther 1982;222:583-588.
50. Heuser IJ, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F: Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 1996;153:93-99.
51. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F: Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 1999;156:949-951.
52. Barden N, Reul JM, Holsboer F: Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 1995;18:6-11.